Lapatinib (L) with weekly paclitaxel (P) as first-line therapy for patients (pts) with HER2+metastatic breast cancer (MBC)

被引：0
|
作者：
Jagiello-Gruszfeld, A.
Tjulandin, Sergei S.
Dobrovolskava, N.
Manikhas, A.
Pienkowski, T.
Knott, A.
DeSilvio, M.
Oliva, C.
机构：
[1] Nzoz Onko Med, Olsztyn, Poland
[2] Russian Acad Med Sci, Canc Res Ctr, Moscow, Russia
[3] Russian Sci Ctr Roentgeno Radiol, Moscow, Russia
[4] St Petersburg City Oncol Dispensery, St Petersburg, Russia
[5] Inst Marii Sklodowskiej Curie, Centrum Onkol, Warsaw, Poland
[6] GlaxoSmithKline Res & Dev Ltd, London, England
[7] GlaxoSmithKline Res & Dev Ltd, Philadelphia, PA USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：246S / 246S
页数：1
相关论文
共 50 条
  • [41] Biomarker analysis of lapatinib with paclitaxel versus paclitaxel as first-line treatment in 580 patients with metastatic breast cancer
    Finn, R. S.
    Press, M. F.
    Dering, J.
    Gomez, H.
    Aziz, Z.
    Arbushites, M.
    Koehler, M.
    Oliva, C.
    Williams, L. S.
    Di Leo, A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 212 - 212
  • [42] Results of first-line weekly paclitaxel (P) plus gemcitabine (G) in metastatic breast cancer (MBC): An AERO phase II trial
    Mousseau, M.
    Serin, D.
    Petit, T.
    Priou, F.
    Zelek, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC)
    Gluck, S.
    Lobo, C.
    Reis, I.
    Lopes, G.
    Carmody, C.
    Tukia, K.
    Hurley, J.
    Seo, P.
    Silva, O.
    Slingerland, J.
    Welsh, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] Bevacizumab Combined with Two-weekly Paclitaxel as First-line Therapy for Metastatic Breast Cancer
    Kountourakis, Panteleimon
    Doufexis, Dimitrios
    Maliou, Savoula
    Karagiannis, Athanasios
    Kardara, Eugenia
    Margari, Charalampia
    Sykoutri, Despoina
    Tzovaras, Alexandros
    Ardavanis, Alexandros
    ANTICANCER RESEARCH, 2010, 30 (07) : 2969 - 2971
  • [45] Weekly paclitaxel and pegylated liposomal doxorubicin (PLD) as first-line therapy in metastatic breast cancer
    Valerio, M. R.
    Fulfaro, F.
    Cicero, G.
    Rinaldi, G.
    Maiorana, O.
    Spinnato, F.
    Intrivici, C.
    Crosta, A.
    Scibilia, C.
    Pizzo, T.
    Vanella, P.
    Gebbia, N.
    ANNALS OF ONCOLOGY, 2006, 17 : VII147 - VII147
  • [46] Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer
    Blum, Joanne L.
    Dees, E. Claire
    Chacko, Aparna
    Doane, Lisa
    Ethirajan, Sukumar
    Hopkins, Judith
    McMahon, Richard
    Merten, Suzan
    Negron, Angel
    Neubauer, Marcus
    Ilegbodu, Des
    Boehm, Kristi A.
    Asmar, Lina
    O'Shaughnessy, Joyce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) : 4384 - 4390
  • [47] Efficacy and safety of first-line bevacizumab (Bev) combined with paclitaxel (Pac): An observational study in 786 patients (pts) with HER2-negative metastatic breast cancer (mBC).
    Klare, P.
    Foerster, F. G.
    Geberth, M.
    Schneeweiss, A.
    Tesch, H.
    Kuemmel, S.
    Schumacher, C.
    Hollburg, W.
    Soeling, U.
    Schmidt, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [48] Safety of the combination of lapatinib (L) plus trastuzumab (T) in patients (pts) with HER2-Positive (+) metastatic breast cancer (MBC)
    Storniolo, A.
    Koehler, M.
    Preston, A.
    Rappold, E.
    Byrne, J.
    Stein, S.
    Ewer, M.
    EJC SUPPLEMENTS, 2007, 5 (04): : 187 - 187
  • [49] Second-line treatment of HER2+metastatic breast cancer (MBC): Trastuzumab (T) beyond progression or lapatinib (L)? A retrospective database study
    Yerushalmi, Rinat
    Feldhamer, Ilan
    Greenberg-Dotan, Sari
    Bitterman, Haim
    Hammerman, Ariel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] Retreatment with trastuzumab (T)-based therapy in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) resistant to lapatinib (L)-based therapy.
    Gori, S.
    Montemurro, F.
    Spazzapan, S.
    Metro, G.
    Foglietta, J.
    Bisagni, G.
    Ferzi, A.
    Silva, R. R.
    Gamucci, T.
    Clavarezza, M.
    Stocchi, L.
    Fabi, A.
    Cognetti, F.
    Torrisi, E.
    Crivellari, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345